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Summary
 
CD80 and CD86 (B7-1 and B7-2) are the ligands on antigen-presenting cells (APCs) which
bind CD28 and deliver the costimulatory signals necessary for T cell activation. The reasons for
the existence of two CD28 binding molecules are not well understood. We created a mutant
version of CTLA4-Ig that could selectively bind CD80 and block CD28-CD80 interaction but
leave CD28-CD86 binding intact. CD80 blockade prevented antigen-induced accumulation
of eosinophils and lymphocytes in the lung of immunized mice, but did not block antigen in-
duced systemic blood eosinophilia or IgE antibody production. No preferential expression of
CD80 could be demonstrated on a population of lung APC consisting mainly of macrophages.
These results indicate that CD80 costimulation is not necessary for the induction of Th2 immune
responses but rather for the maintenance or amplification of lung inflammatory responses.
 
T
 
wo APC surface molecules, CD80 and CD86, have
been identified as ligands for CD28 and CTLA-4 on
T cells. Although CD80 and CD86 only share 26% amino
acid homology and bind CD28 utilizing overlapping but
distinct binding determinants, they bind with similar avid-
ities and both provide potent costimulatory function for
T cells (1–7). It is currently controversial whether the sig-
nals provided to the T cells upon interaction of CD80 and
CD86 with CD28 are qualitatively different, and lead to
the development of functionally distinct types of T cells (8–
12). In this context CD80 and CD86 have quite distinct
intracellular domains (1, 2), which raises the possibility that
CD80 or CD86 may also deliver different signals to the
APC during cognate interaction.
Recent studies offer evidence of differential roles for
CD80 and CD86 during in vivo immune responses. Many
of these suggest that it is not the ability to mount an im-
mune response which is altered by blockade of either
CD80 or CD86, but that instead the outcome of the im-
mune response may differ. Kuchroo et al. (8) found that in
a model of experimental allergic encephalomyelitis (EAE),
where disease is abrogated by the development of Th2 cells
and exacerbated by a Th1 immune response, anti-CD80
treatment reduced disease incidence while anti-CD86 in-
creased disease severity. In apparent contrast to these findings
Lenschow et al. (9) found that in a model of autoimmune
diabetes (a disease also mediated by Th1 cells) anti-CD80
increased and accelerated disease incidence while anti-
CD86 blocked the development of disease. However, both
studies suggest that CD80 and CD86 may act by influenc-
ing the commitment of T cells to a Th1 or Th2 phenotype.
Further support of a differential role for CD80 and CD86
comes from studies where treatment of mice with anti-
CD80 F(ab
 
9
 
) but not anti-CD86 mAb prevented clinical
relapse and epitope spreading in EAE (10), and from a
model of murine lupus where auto-Ab production was
preferentially dependent on CD86 costimulation (11). Some
in vitro studies also support a role for CD86 costimulation
in the development of Th2 cells (12).
While CD28 is expressed by all murine peripheral T
cells, CTLA-4 only appears after T cell activation (13, 14)
and binds CD80 and CD86 with much higher avidity than
CD28 (7). A soluble form of CTLA-4, CTLA4-Ig, has
been developed and found to be a highly effective antago-
nist of CD28-CD80/CD86 interactions (6, 15, 16). We
have used a model of Th2-dependent Ag-induced airway
eosinophilia to show that eosinophil recruitment and Ab
production are completely abrogated by the expression of
transgenic mCTLA4-H
 
g
 
1 (16a), thus Th2 cell effector
functions are totally dependent on CD28-mediated costim-
ulation in this system. To investigate the role of individual
CTLA-4 ligands we created a mutant form of CTLA4-Ig,
termed Y100F-Ig, which binds to CD80 but not CD86.
We used Y100F-Ig as a selective antagonist to define the
role of CD80 costimulation in Ag-induced airway eosino-
philia.
 
Materials and Methods 
 
Reagents.
 
Y100F-Ig is a mutant human CTLA4-Ig in which
tyrosine at position 100 is substituted with phenylalanine. The
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molecule was constructed by PCR using oligonucleotide-directed
mutagenesis (17). CTLA4-Ig and Y100F-Ig were purified from
culture media of stably transfected Chinese hamster ovary (CHO)
cells.
 
FACS
 
Ò
 
 Analysis.
 
Analysis of CTLA4-Ig and Y100F-Ig bind-
ing to CHO cells stably transfected with murine CD80 or CD86
was carried out by incubating cells with CTLA4-Ig or Y100F-Ig
for 2 h at 23
 
8
 
C then staining with FITC-conjugated goat anti–
human IgG. Binding was analyzed on a FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA). Mean fluorescence intensity
was determined from data histograms using PC-LYSYS. Analysis
of BAL macrophages was carried out by staining cells in 96–well
round bottom plates at 10
 
5–6
 
/well for 10–15 min on ice using
anti-CD80-FITC or anti-CD86-PE (PharMingen, San Diego,
CA) appropriately diluted in PBS 
 
1
 
 2% FCS. 2.4G2 (10 
 
m
 
g/ml)
was used to inhibit Fc
 
g
 
RII-mediated uptake. Flow cytometric
analysis was performed on a FACSort
 
Ò
 
 (Becton Dickinson) using
the CellQuest software. 10,000 live gated cells, as identified by
Propidium Iodide dye exclusion, were analyzed and macrophages
gated for by size and granularity.
 
Mice.
 
C57BL/6J mice were bred and maintained at the Ani-
mal Facility of the Wellington School of Medicine. All animal
experimental procedures used in this study were approved by the
Wellington School of Medicine Animal Ethics Committee, and
carried out in accordance with the guidelines of the University of
Otago (New Zealand).
 
OVA-induced Airway Inflammation.
 
Mice were primed i.p.
with 2 
 
m
 
g OVA (Sigma Chem. Co., St. Louis, MO) in 100 
 
m
 
l
alum adjuvant (SERVA, Heidelberg, Germany) on day 0 and
boosted i.p. with 2 
 
m
 
g OVA/alum at day 10. 4 d after the last i.p.
immunization mice were anaesthetized by injection of a mixture
of ketamine and xylazine (Phoenix, Auckland, New Zealand),
and 100 
 
m
 
g OVA in a 50-
 
m
 
l volume of PBS was administered by
intranasal inoculation. 4 d later mice were killed, the trachea can-
nulated, and a BAL performed by flushing lung and airways three
times with 1 ml PBS. BAL cells were counted, spun onto glass
slides using a cytospin (Shandon Southern Products Ltd., Ast-
moor, UK), and stained with Diff-Quik (Dade, Diagnostics, Pan-
mure, Auckland) according to the manufacturer’s instructions.
Percentages of macrophages, lymphocytes, neutrophils and eosin-
ophils were determined microscopically using standard histologi-
cal criteria.
 
ELISA.
 
Polyvinyl chloride 96-well plates (Nunc, Roskilde,
Denmark) were coated overnight at 
 
1
 
4
 
8
 
C with OVA (10 
 
m
 
g/
well) and blocked with 10% BSA in PBS for 60 min at room
temperature (RT). Twofold dilutions of serum were added and
incubated for 2 h at RT. Appropriate dilutions of detecting Ab
and then peroxidase-labeled streptavidin (Sigma) were added for
1 h at RT. The isotype-specific anti-mouse IgG1 was from Sero-
tec (Oxford, UK), anti-mouse IgG2a was from PharMingen, the
3-11 monoclonal anti-mouse IgE was generously provided by
Dr. Christoph Heusser (Ciba, Basel, Switzerland). 100 
 
m
 
l of
freshly made 1 mM ABTS (Sigma) in citrate phosphate buffer,
pH 9.2, and 0.03% H
 
2
 
O
 
2
 
 was added to each well to develop the
reaction. The reaction was stopped by adding 100 
 
m
 
l 2 mM
NaAzide and the plates read at 414 nm using an Anthos Hill
(Salzburg, Austria) plate reader. Ab titers are expressed in Units/
ml (reciprocal of 50% Ab titer).
 
Results
 
Y100F-Ig Binds to CD80 and not CD86.
 
We have pre-
viously shown that amino acid residues in the conserved
MYPPPY motif of CTLA4-Ig are critical for the binding
of CTLA4-Ig to CD80 (17). Mutation of the first tyrosine
in this motif (Tyr 100) to alanine resulted in reduced bind-
ing to CD80 but abolished binding to CD86 (5). However,
mutation of Tyr 100 to phenylalanine resulted in a mole-
cule (Y100F-Ig), which retained wild-type binding to CD80,
but with no apparent binding to CD86. As shown in Fig. 1,
FACS
 
Ò
 
 analysis demonstrated that Y100F-Ig and CTLA4-Ig
bind equally well to CHO cells expressing murine CD80.
In contrast, binding of Y100F-Ig to CHO cells expressing
murine CD86 was undetectable even at concentrations as
high as 100 
 
m
 
g/ml. These data confirm that Y100F-Ig can
be used to selectively block CD80-mediated costimulation
to T cells.
 
Effect of Y100F-Ig on Lung and Blood Eosinophilia.
 
We used
Y100F-Ig as a selective antagonist to define the role of
CD80 costimulation in a model of Ag-induced airway
eosinophilia. In this model mice are immunized twice i.p.
with 2 
 
m
 
g OVA in alum adjuvant, and then challenged in-
tranasally with OVA in soluble form. The subsequent Th2-
dependent lung inflammatory response is characterized by
the presence of large numbers of eosinophils and lympho-
cytes in the BAL fluid, lung and airway tissue. OVA-spe-
cific IgE and IgG1 Abs are detected in the serum.
Mice treated with CTLA4-Ig, Y100F-Ig or the control
molecule L6-Ig were subjected to the OVA airway immu-
nization protocol. Treatment was continued throughout
the experiment with i.p. injections of 400 
 
m
 
g CTLA4-Ig,
Y100F-Ig or L6-Ig every 48 h beginning 48 h before the
first OVA immunization. The serum levels of CTLA4-Ig
and Y100F-Ig at the end of the experiment were 70–75
and 38–40 
 
m
 
g/ml, respectively.
Eosinophil infiltration into the airways of OVA-immu-
nized, airway challenged mice was blocked by treatment
with either CTLA4-Ig or Y100F-Ig (Fig. 2 
 
A
 
). The num-
bers of lymphocytes in the BAL were also strongly dimin-
ished in these two groups compared to L6-Ig. Because in
vivo injection of anti-CD4 or anti-IL-5 Ab before the in-
tranasal challenge completely abrogates the appearance of
Figure 1. Y100F-Ig binds to murine CD80 but not CD86. Y100F-Ig
(circles) and wild-type CTLA4-Ig (squares) were incubated with Chinese
Hamster Ovary (CHO) cells stably transfected with murine CD80 or
CD86 and binding determined by FACSÒ analysis. 
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eosinophils in the BAL (18), we interpreted the result in
Fig. 2 
 
A
 
 as suggesting that both CTLA-4 Ig and Y100F-Ig
interfere with the generation of IL-5-producing Th2 cells.
Indeed, CTLA4-Ig also inhibited the OVA-induced ap-
pearance of eosinophils in the blood (Fig. 2 
 
B
 
). This re-
sponse precedes accumulation of eosinophils in the lung,
and is also dependent on IL-5 production (19). Surpris-
ingly, however, Y100F-Ig failed to inhibit blood eosino-
philia, with levels being comparable in Y100F-Ig– and L6-
Ig–treated mice (Fig. 2 
 
B
 
). Thus, CTLA4-Ig and Y100F-Ig
have different effects on systemic eosinophilia. CTLA4-Ig
most likely acts on IL-5 secretion by T cells, and therefore
blocks all eosinophil responses. The effects of Y100F-Ig are
more selective in that it prevents the accumulation of eosin-
ophils in the lung without blocking systemic IL-5 secre-
tion.
 
Effect of Y100F-Ig on Ab Production.
 
To determine the
effect of CD80 costimulation on Ab production OVA-spe-
cific IgG and IgE titers were measured in CTLA4-Ig–,
Y100F-Ig–, and L6-Ig–treated mice. As expected all Ab
isotypes were lowered by CTLA4-Ig treatment (Fig. 3).
Levels of IgG1, IgG2a and IgE were similar in Y100F-Ig–
and L6-Ig–treated mice (Fig. 3). This result indicates that
OVA-specific T cells that can deliver help to B cells have
been generated in Y100F-Ig–treated mice. These T cells
must be capable of IL-4 secretion in vivo since the devel-
opment of an Ag-specific IgE response has been shown to
be entirely dependent upon production of IL-4 (20, 21).
The high levels of IgG1 and IgE, and low levels of IgG2a
in Y100F-Ig– and L6-Ig–treated mice (Fig. 3) indicated
that both groups generated a good Th2 response but little
or no Th1 response.
 
Expression of CD80 and CD86 in the Lung.
 
It was pos-
sible that T cells capable of secreting both IL-4 and IL-5
could accumulate in the lung of Y100F-Ig–treated mice,
but that once in the lung their further activation was
blocked because of the preferential expression of CD80
ligands by local APC. This could lead to termination of the
response in the lung due to lack of production of T cell–
derived cytokines and chemotactic factors necessary for the
amplification of the response. To address this we stained
lung macrophages, isolated from OVA-immunized and air-
way challenged mice, with Abs to CD80 and CD86. Al-
though CD80 was not detectable by FACS analysis, stain-
ing for CD86 was observed (Fig. 4). Other lung resident
APC, such as dendritic cells, are also reported to express
both CD80 and CD86 (22). Together, these results rule
Figure 2. Treatment with Y100F-Ig inhibits lung (A) but not blood
(B) eosinophilia in OVA-immunized, airway-challenged mice. C57BL/6
mice were primed twice i.p. with 2 mg OVA in alum adjuvant on day 0
and day 10 then given an intranasal challenge with 100 mg OVA in PBS 4
d after the last i.p. immunization. BAL fluid was collected 4 d after intra-
nasal challenge. Differential cell counts were made on BAL cytospins and
blood smears stained with Diff-Quik. Mice were treated i.p. with 400 mg
of either CTLA4-Ig, Y100F-Ig or L6-Ig every 48 h. Values represent the
mean 6 SE for groups of 5–7 mice. Results shown are representative of
four (A) and two (B) experiments.
Figure 3. Treatment with
CTLA4-Ig, but not Y100F-Ig,
inhibits the production of OVA-
specific IgG1, IgG2a and IgE.
Mice were treated with CTLA4-
Ig, Y100F-Ig or L6-Ig and
subjected to a protocol of OVA
immunization and airway chal-
lenge as detailed in Fig. 2. Serum
was collected at the time of death
and OVA-specific antibody lev-
els determined by ELISA. Values
represent serum antibody titers
for individual mice. Shown are
the results of two pooled experi-
ments. 
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out the possibility that Y100F-Ig treatment can selectively
block the activation of  T cell responses because of selective
expression of CD80 ligands on local APC. This system dif-
fers from another disease model in which CD80 was the
predominant costimulatory molecule expressed at the site
of inflammation and in which CD80 blockade was effec-
tive (10).
 
Discussion
 
The simultaneous blockade of CD80 and CD86 causes
complete inhibition of most T cell responses, either by pre-
venting T cell activation altogether, or by inhibiting T
cell–dependent recruitment of effector immune responses
(15, 16, 23–25). Individually, the two molecules appear to
play largely redundant roles (25–27) although the blockade
of either CD80 or CD86 has been reported to cause im-
mune deviation in some experimental systems (8, 9, 11,
12). With the present study we propose that additional
mechanisms exist by which the blockade of CD80/CD86-
mediated costimulation causes inhibition of immune re-
sponses. Using an OVA airway immunization protocol, we
observed that selective CD80 blockade had no effect on
the induction of systemic Th2-type immune responses but
strikingly inhibited the infiltration of eosinophils, and to a
lesser extent lymphocytes, into the lungs and airways of in-
tranasally challenged mice. This was not due to induction
of immune deviation by Y100F-Ig treatment, as other
Th2-type responses, e.g., blood eosinophilia and IgE pro-
duction, were not affected by Y100F-Ig treatment. Evi-
dence of Th1 responses could not be found in Y100F-
Ig–treated mice as titers of OVA-specific IgG2a were not
increased in comparison to L6-Ig–treated controls (Fig. 3).
Failure to observe BAL eosinophilia in Y100F-Ig–treated
mice was not due to differences in the kinetics of the re-
sponse, as different time points after intranasal inoculation
were analyzed, nor to the use of a limiting amount of anti-
gen in the intranasal challenge. Previous studies (Harris, N.,
unpublished observation) had shown that intranasal inocu-
lation of 100-fold less OVA than used in this study was still
sufficient to induce a maximum eosinophil response. Also,
intranasal Ag challenge was followed by comparable in-
creases in blood eosinophilia in Y100F-Ig– and L6-Ig–treated
mice, again suggesting that a sufficient amount of Ag was
used. It is possible that CD80 blockade prevents acquisition
by T cells of the adhesion molecules involved in recircula-
tion through tissues, or the upregulation of their ligands on
endothelium (28). We think this is rather unlikely, as T cells
could be recovered from the lung of Y100F-Ig–treated
mice, and these cells did produce IL-5 upon in vitro restim-
ulation with anti-CD3 (data not shown). A perhaps more
likely possibility is that in nonlymphoid tissues the amount
of T cell costimulatory signals in the form of CD86 may be
limiting, leading to the need for further signaling provided
by CD80. The later appearance of CD80 would serve to
prolong or increase the intensity of costimulatory signals
delivered by the APC to the T cell, leading to the mainte-
nance and amplification of the local inflammatory response.
In this regard, a higher costimulatory threshold may be pre-
ferred in tissues to prevent injury caused by inappropriate
immune activation.
Migration of different cell populations to the lung is un-
der the control of a number of factors (29–31) whose regu-
lation and function are still largely undetermined. Defini-
tion of the precise consequences of CD80 blockade in this
context is therefore not possible at this stage. However, it
is clear from the present study how the blockade of indi-
vidual T cell costimulatory signals can have complex effects
on T cell responses, and may lead to striking differences in
responses in tissues.
Figure 4. CD86 is expressed on lung macrophages from OVA-immu-
nized and airway-challenged mice. BAL cells were collected from mice
subjected to a protocol of OVA immunization and airway challenge as
detailed in Fig. 2 and CD80/CD86 expression determined by FACSÒ
analysis. Filled histogram, non-stained samples; empty histogram, samples
stained as indicated.
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